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INTRODUCTION
Following tissue injury and vessel wall stimulation, a number
of events are triggered to recruit circulating blood cells to
specific sites, including platelet activation, endothelial cell
stimulation, and leukocyte transmigration through the
endothelium to mediate the host defense mechanisms of
inflammation, thrombosis and wound healing (Celi et al., 1997;
Etzioni, 1996). These processes are highly regulated and
involve various cell adhesion molecules expressed by both the
endothelium and circulating blood cells. The involved cell
adhesion molecules belong to four major superfamilies:
integrins, immunoglobulin (Ig)-like proteins (CAMs), selectins
and cadherins (Rosales et al., 1995). Leukocytes constitutively
express α2 integrins; integrin αIIbβ3 is the major platelet
integrin, whereas integrin αvβ3 is predominantly expressed on
endothelial cells. CAMs are expressed on endothelial cells,
leukocytes and platelets, and serve as counter receptors/ligands
for integrins. These interactions between integrins and Ig-like
CAMs play an important role in leukocyte transmigration
through the endothelium (Vaporciyan et al., 1993; Wahl et al.,
1996).
Cytokines released at the inflammatory site induce the
expression of various CAMs on the endothelium. Leukocytes
adhere to these molecules through their surface integrins,
which accounts in part for the recruitment of leukocytes during
an inflammatory or immune reaction (Chiba et al., 1999).
Leukocyte adhesion to endothelial cells triggers intracellular
signals that in turn, lead to the opening of the junctions
between neighboring endothelial cells, facilitating leukocyte
transmigration (Celi et al., 1997). The mechanism involved in
the opening of the junction during leukocyte transmigration is
not yet known. It has been suggested that phosphorylation of
certain junctional proteins may regulate this process (Dejana
et al., 1995; Takaishi et al., 1997). Recently, a murine Ig
superfamily molecule, JAM, has been identified (Martin-
Padura et al., 1998). This murine JAM is expressed at cell-cell
junctions in endothelial and epithelial cells, and has been
implicated in monocyte transmigration (Del Maschio et al.,
1999). Subsequently, Ozaki and colleagues reported the
i entification of human and bovine homologs of JAM and
showed that it redistributes from the cell-cell junction to the
cell surface upon activation of endothelial cells by combined
treatment with TNF-α and IFN-γ (Ozaki et al., 1999).
Monoclonal antibody F11 is a potent platelet agonist
(Kornecki et al., 1990), as it induces platelet granular secretion
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We have previously reported the purification and
characterization of a 32 kDa platelet surface glycoprotein
that is recognized by the stimulatory monoclonal antibody,
F11. The cDNA has been cloned and found to encode the
human homolog of the murine junctional adhesion
molecule, JAM; we therefore named this human homolog
JAM-1. Northern blot analysis indicated that JAM-1
mRNA is expressed as multiple species, the predominant
transcript being ~4.0 kb in size. Genetic mapping analysis
using fluorescence in situ hybridization (FISH) showed that
it is localized to chromosome 1q21.1-21.3. Recombinant
JAM-1, when expressed in Chinese hamster ovary (CHO)
cells, localized to the cell membrane with intense staining
where two adjacent cells actually made contact with each
other, suggesting that, similar to murine JAM, human
JAM-1 may also localize at the cell-cell junction. In well-
spread cells, JAM-1 co-localized with F-actin at the cell-cell
contacts and at the membrane ruffles, but not at the stress
fibers. Interestingly, JAM-1 localizes only to the cell-cell
junctions formed by two transfected cells and not to the
cell-cell junctions formed by a transfected cell with an
untransfected cell, suggesting that JAM-1 may facilitate
cell adhesion through homophilic binding. In addition,
human platelets specifically bind to a monolayer of CHO
cells expressing human JAM-1, further supporting
homophilic interactions. The results presented here
indicate that JAM-1, a receptor for a platelet-activating
antibody, is the human homolog of the junctional adhesion
molecule. JAM-1 is a single copy gene, which is
constitutively expressed on various tissues and cells, and
may be involved in cell to cell adhesion through homophilic
interaction. 
Key words: JAM-1, CAM, Platelet, Activation, Adhesion,
Homophilic
SUMMARY
Characterization and chromosomal localization of
JAM-1, a platelet receptor for a stimulatory
monoclonal antibody
Ulhas P. Naik 1,*, Meghna U. Naik 1, Kristin Eckfeld 1, Patricia Martin-DeLeon 1 and Jozef Spychala 2
1Department of Biological Sciences, University of Delaware, Newark, DE 19716, USA
2Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
*Author for correspondence (e-mail: unaik@udel.edu)
Accepted 20 November 2000
Journal of Cell Science 114, 539-547 © The Company of Biologists Ltd
RESEARCH ARTICLE
540
and platelet aggregation. F11 recognizes a 32 kDa glycoprotein
as an antigen and crosslinks it to the FcγRII receptor. As a
result of this crosslinking, a signaling cascade is activated that
involves a rise in intracellular Ca2+, activation of protein kinase
C, intracellular protein phosphorylation and activation of
integrin αIIbβ3, the fibrinogen receptor (Naik et al., 1995;
Wang et al., 1995). F11 also potentiates the effect of other
physiological agonists in the absence of FcγRII receptor
engagement. We have previously reported the purification of
the F11 antigen from human platelets (Naik et al., 1995). Here
we report the cloning, cellular expression and chromosomal
localization of the F11 antigen gene, which has also been
independently identified elsewhere (Sobocka et al., 2000).
Amino acid analysis indicates that the F11 antigen is a member
of the Ig-superfamily of cell adhesion molecules. The deduced
amino acid sequence of the F11 antigen has about 69% identity
to the murine junctional adhesion molecule (JAM) and is
identical to its human homolog. We therefore named the F11
antigen, the human homolog of JAM, JAM-1. 
MATERIALS AND METHODS
Geneticin (G418), Lipofectamine and tissue culture media were
purchased from Gibco-BRL (Gaithersburg, MD). Unless specified
otherwise, all other chemicals were of analytical grade purchased
from Sigma (St Louis, MO). 
cDNA cloning of JAM-1
Two degenerate primers, sense 5′-AT(T/C/A)CC(T/C/A/G)GA(A/G)-
AA(T/C)AA(T/C)CC-3′ and antisense 5′-(T/C)TT(A/G)AA(-
G/A/T/C)GT(A/G/T)AT(T/C/G/A)CC-3′, corresponding to the N-
terminal and the internal peptide sequence of F11 antigen/JAM-1,
respectively (Naik et al., 1995), were synthesized and used in RT-PCR
reactions using total RNA from freshly isolated human platelets. The
PCR product obtained was directly subcloned into the PCR 2.1 vector
(Clontech) by TA-TOPO cloning. Sequencing and GenBank searching
revealed several partial ESTs. EST AA101561 was obtained from the
American Type Culture Collection (ATCC, Manassas, VA) and used
to screen a human liver cDNA library (Clontech) using the described
procedure (Spychala et al., 1996). Consequently, several positive
clones were obtained, one of which was a full-length cDNA. The
sequence has been deposited in the GenBank database under the
Accession Number AF172398. 
Construction of expression plasmids
A hemoagglutinin (HA) epitope (AYPYDVPDYA) was inserted
between the signal peptide and the first Ig domain of JAM-1 using
PCR. The resultant cDNA was directionally cloned into the
mammalian expression vector pcDNA3.1, and the sequence of the
resulting clones was verified using automated sequencing. This
epitope-tagging allowed us to follow the expression of recombinant
JAM-1, and distinguish it from endogenous JAM-1. 
Antibodies
FITC-conjugated phalloidin was purchased from Molecular Probes
(Eugene, OR). TRITC-labeled anti-mouse immunoglobulin G (IgG)
was purchased from Jackson ImmunoResearch Laboratories (West
Grove, PA). Mouse monoclonal antibody against the HA-tag was
purchased from Babco (Richmond, CA). HRP-conjugated anti-mouse
and anti-rabbit antibodies were purchased from Amersham Pharmacia
Biotech (Piscataway, NJ).
Cell culture
Chinese hamster ovary (CHO) and human breast cancer cells (T47D)
were obtained from ATCC. CHO cells were maintained in DMEM
supplemented with 10% fetal bovine serum (FBS), 100 units/ml of
penicillin and 100 µg/ml streptomycin. T47D cells were maintained
in RPMI-1640 supplemented with 10% FBS, 10 µg/ml insulin, 100
units/ml penicillin and 100 µg/ml streptomycin. All cells were
cultured in a humidified atmosphere of 5% CO2 in air.
Transfections
Both CHO and T47D cell lines were transfected using Lipofectamine
(GibcoBRL) following the manufacturer’s protocol. Control cells
were transfected with an empty pcDNA plasmid. G418 was added to
the culture medium 24 hours after transfection at a final concentration
of 500 µg/ml, and the resistant individual colonies were isolated to
obtain single cell clones, or expanded as pools of stably transfected
cells. The expression of JAM-1 was determined by immunoblotting.
All the cells were thereafter maintained in culture medium containing
300 µg/ml of G418. 
Immunofluorescence
JAM-1-overexpressing CHO cells were cultured in Lab-TekII 8-
chambered coverglass slides (Nunc, Naperville, IL), fixed in freshly
prepared 4% paraformaldehyde for 10 minutes, permeabilized in 0.2%
Triton X-100 for 5 minutes, and blocked with phosphate buffered
saline (PBS) containing 3% BSA (blocking solution) for 1 hour. Cells
were then incubated with mouse anti-HA antibody (1:150) overnight
at 4oC. After incubation, cells were washed three times with blocking
solution and incubated with TRITC-labeled Donkey anti-Mouse IgG
secondary antibody (1:200) for 1 hour at room temperature. For
staining of filamentous actin, FITC-conjugated phalloidin (1:100) was
included during incubation along with the secondary antibody. Cells
were washed three times in blocking solution with a final wash of
PBS. Slowfade (Molecular Probes) was added to minimize fading of
the fluorescence intensity. Confocal microscopy was performed using
a Zeiss LSM510 laser-scanning microscope.
FISH analysis
The JAM-1 cDNA clone was biotinylated by nick translation and used
as a probe in FISH studies as described previously, with some
modifications (Deng et al., 1997; Nagle et al., 1994). Approximately
400 ng of the biotin-labeled cDNA was co-precipitated with sonicated
herring sperm DNA and dissolved in hybridization solution [50%
(v/v) formamide, 2× SSC and 10% (w/v) dextran sulfate (Hybrisol
VII, Oncor, Gaithersburg, MD)]. The probe was then denatured for 8
minutes at 75oC and immediately applied to human metaphase
spreads prepared from peripheral lymphocyte cultures for overnight
hybridization. Post-hybridization washes were brief (2 minutes) and
carried out at 37oC. The detection and amplification of the signal was
performed with FITC-labeled avidin and anti-avidin (Oncor) and
chromosomes were counterstained with diaminophenylinodole
(DAPI) in p-phenylenediamine (0.1 µg/ml) for microscopic
examination. The slides were viewed with a Zeiss Axioskop equipped
with a Sensys cooled CCD camera (Photometrics, Tucson, AZ).
Image capture was performed with software from IPLab Spectrum
Module (Scanalytics, Fairfax, VA). Separate images of DAPI-banded
chromosomes and FITC hybridization signals were acquired and
electronically superimposed.
Northen blot analysis
Multiple tissue northern (MTN) blots were purchased from Clontech.
An EcoRI fragment (~800 bp) of JAM-1, which includes only the
coding region, was used as a probe. The northern blots were washed
with stringent conditions according to the manufacturer’s instructions.
A β-actin probe was used to test for equal loading of the mRNA. 
RT-PCR
Total RNA was isolated from K562 cells using TRIZOL reagent
(GibcoBRL). Poly(A)+ RNA was isolated using an oligo(dT) cellulose
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column, following the manufacturer’s protocol. A reverse
transcriptase reaction was carried out for 30 minutes at 50oC using 1
µg of total RNA or 0.1 µg of poly(A)+ RNA per reaction. The first 10
cycles of PCR amplification were carried out at 94oC for 30 seconds,
45oC for 30 seconds, 68oC for 2 minutes, and during the next 20
cycles, the elongation time was extended to 3 minutes. Various
primers derived from JAM-1 cDNA as indicated (see Fig. 3A) were
used to amplify specific size products. PCR products were analyzed
using agarose gel electrophoresis.
Platelet adhesion
Platelets were isolated from healthy donors by venipuncture using
sodium citrate as an anticoagulant (Naik et al., 1991). Platelet-rich
plasma (PRP) was prepared by centrifugation at 200 g for 10 minutes.
PRP was diluted with PBS to 1× 06 platelets/ml and 200 µl of this
platelet suspension was added to the cover glass
chambers pre-plated with a monolayer of CHO
cells mock transfected or transfected with JAM-1.
After 30 minutes of incubation at room
temperature, the chambers were washed three times
and then incubated for 10 minutes with FITC-
labeled cyclic RGD peptide XL086 (Mousa et al.,
2000). This peptide specifically binds to the
platelet-specific surface integrin αIIbβ3 and can be
used to detect bound platelets (Mousa et al., 2000).
The number of platelets bound to the monolayer
was quantified by counting randomly at 100×
magnification using confocal laser microscopy.
RESULTS
cDNA cloning of JAM-1
We have previously reported the purification
and partial amino acid sequence of the platelet
surface protein recognized by the stimulatory
antibody F11 (Naik et al., 1995). To clone this
platelet surface protein, degenerate primers
derived from N-terminal and internal amino
acid sequences of F11 antigen were used in
RT-PCR reactions. The amplified PCR product
was cloned into the pCR 2.1 vector and
sequenced. A GenBank database search using
this cDNA sequence revealed several partial
EST entries. We obtained an EST clone from
ATCC and used the cDNA insert as a probe to
screen a human liver library. We isolated a 1.9
kb cDNA clone of the F11 antigen containing
a 900 bp open reading frame (Fig. 1A). The
deduced amino acid sequence of the F11
antigen is ~69% identical to the recently
identified mouse junctional cell adhesion
molecule, JAM (Fig. 1B) (Martin-Padura et
al., 1998), and identical to the human homolog
of JAM termed JAM-1 (Ozaki et al., 1999). We
therefore conclude that the F11 antigen is
JAM-1. The cDNA encodes the 299 amino
acid JAM-1 precursor containing a 27 amino
acid plasma membrane localization signal
peptide. The predicted signal peptide cleavage
site corresponds to the N-terminal sequence of
the native mature protein. JAM-1 is a type one
integral membrane protein with a single
transmembrane domain of 19 hydrophobic residues (V237-
V254), and also shows significant similarity to other cell
adhesion molecules such as VCAM-1 and NCAM. The
extracellular domain has two C2-type disulfide-linked Ig-like
domains; JAM-1 also has a short, 42-amino acid cytoplasmic
tail. The protein sequence of JAM-1 contains two putative N-
glycosylation sites (N185 and N191) on its external surface and
several consensus phosphorylation sites for PKC cAMP-
dependent protein kinase A (PKA) and casein kinase II within
the cytoplasmic domain. In addition, the cytoplasmic domain
contains two tyrosine residues separated by 18 amino acid
residues in consensus for tyrosine phosphorylation and binding
to the SH-2 domain (Jackson et al., 1997a). VE-JAM, another
junctional adhesion molecule belonging to the Ig-superfamily
Fig. 1. Sequence analysis of JAM-1.(A) cDNA and deduced protein domain structure
of JAM-1. The 299 amino acid polypeptide precursor has a 27 amino acid signal
peptide (SP), two C2-type Ig domains, a transmembrane domain (TM) and a 42 amino
acid cytoplasmic domain. Two N-glycosylation (N) sites are present on the second Ig
domain. Several serine/threonine protein kinase phosphorylation sites and two tyrosine
phosphorylation sites (P) are present in the cytoplasmic domain. (B) Deduced amino
acid sequence comparison of JAM-1 with murine JAM and human VE-JAM. 
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and having one amino acid residue less than JAM-1, has
recently been cloned (Palmeri et al., 2000). VE-JAM has ~32%
identity to murine JAM or its human homolog JAM-1 (Fig.
1B). Recently, Cunningham et al. have cloned another member
of the JAM family of cell adhesion molecules having 43%
similarity to JAM-1 which maps to chromosome 21q21.2
(Cunningham et al., 2000). These results suggest that there is
a family of cell adhesion molecules belonging to JAM-1.
Expression of JAM-1
Northern blot analysis performed to determine the expression
pattern of JAM-1 indicates the presence of multiple specific
bands indicative of closely related species or splicing variants
of JAM-1 (Fig. 2A). The 1.9 kb transcript likely corresponds
to the cloned JAM-1 species; however, two other major
transcripts that were consistently seen even at high stringency,
the 2.4 and 4.0 kb species, may represent JAM-1 molecular
variants. The more abundant 4.0 kb transcript is expressed at
high levels in the pancreas, placenta, lung, and kidney, and at
low levels in the heart and liver. A similar pattern of expression
was observed in various cancer cell lines, with the 4.0 kb
species as the predominant transcript (Fig. 2B). It is thus
possible that, like most of the CAMs, JAM-1 may also be
expressed in different cells in different forms. Immunoblotting
and immunohistological studies have shown that in addition to
platelets and leukocytes, JAM-1 is also localized to the
epithelial and endothelial cells of various tissues (Liu et al.,
2000). 
To determine if the larger transcripts of JAM-1 resulted from
insertion of additional exons in the coding region of JAM-1,
we performed RT-PCR analysis using both poly (A)+ RNA and
total RNA isolated from K562 cells, which contain high levels
of the larger transcripts. Fig. 3A shows the primers used to
amplify various fragments of JAM-1 cDNA. Any insertion of
exons occurring as a result of alternative splicing in either the
coding region or in the 3′-untranslated region (UTR) will
produce an insert of larger than expected size. However, only
expected-size products were amplified (Fig. 3B), suggesting
that there may not be any insertions occurring in the coding
region and in the 3′-UTR. These results suggest that the larger
transcripts may have arisen from an extended 3′ or 5′-UTR. 
I olation of full-length cDNA of JAM-1
Unigene database search revealed several EST clones having
large insert size. We obtained from ATCC an EST clone
(AI923135) that had a 3.7 kb insert. Sequence analysis of this
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Fig. 2. Expression of JAM-1 mRNA in
various human tissues and cell lines. Multiple
tissue northern (MTN) blots of human tissues
(A) and human cancer cell lines (B) were
probed at high stringency using JAM-1 cDNA
(coding region) as a probe. Three distinct
species of message were detected, of which a
1.9 kb message corresponds to JAM-1
(arrow). The abundantly expressed 4.0 kb and
less intense 2.4 kb bands are also visible.
However, these bands are expressed in trace
amounts in the brain.
Fig. 3. RT-PCR amplification of JAM-1 transcripts from K562 cells.
(A) Primers used in RT-PCR experiments with expected sizes of the
products. Oligo dT and four specific primers – S1 and S3 (sense); S2
and S4 (antisense) derived from JAM-1 cDNA were used in PCR
amplification. S1 and S2 should amplify 1.9 kb product, whereas S3
and S2, are expected to generate 1.0 kb product. S1 and S4 should
produce 0.9 kb product. (B) Agarose gel showing the RT-PCR-
amplified products. PolyA+ RNA (lanes 2-6), or Total RNA (lanes 7-
11) prepared from K562 cells were used in RT-PCR reactions as
described in Materials and Methods. Different sets of primers were
used as indicated to amplify specific sizes of cDNA fragments. Lane
1 and lane 12 are molecular size markers.
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clone indicated that the JAM-1 message has a 2.7 kb long 3′
UTR that contains several repeats of Alu-like repetitive
elements. The 3′ end of this clone also has the polyadenylation
signal that is not present in any of the earlier reports published
on human JAM-1.
Chromosomal localization of JAM-1
To ascertain whether the different sized transcripts of JAM-1
originated from a single gene, the chromosomal localization of
JAM-1 was determined using FISH (Deng et al., 1997; Nagle
et al., 1994). In over 20 metaphases analyzed, FISH signals
were exclusively detected on one or both homologs of
chromosome 1, and DAPI-banding localized the gene to band
q21.1 to q21.3 (Fig. 4). The low intensity of the signal could
be due to the use of a cDNA fragment (~1.0 kb) as a probe
instead of genomic DNA. A Unigene search of the GenBank
database further confirmed and narrowed the location of the
gene for JAM-1 to a 1.7 cM interval between the D1S2705
(175.1 cM) and D1S2768 (176.8 cM) microsetallite markers
(http://www.ncbi.nlm.nih.gov/UniGene/clust.cgi?ORG=Hs&
CID=11482). Together these results indicate that the observed
multiple transcripts are the product of either a single gene or
highly similar, tightly-linked genes. It should be noted that
mutations responsible for several human genetic disorders map
near this region of human chromosome 1, including Gaucher’s
disease, glaucoma, prostate cancer and Alzheimer’s disease
(http://www.ncbi.nlm.nih.gov/disease/chr1-4.html). 
Expression of recombinant JAM-1 in CHO cells and
its cellular localization
To determine the intracellular localization and function of
JAM-1 more specifically, an HA epitope was engineered at the
N terminus of JAM-1 between the signal peptide and the first
Ig domain, and the resulting protein was expressed in CHO and
T47D cells. The level of expression was monitored by western
blotting using an anti-HA monoclonal antibody. As shown by
confocal microscopy, recombinant JAM-1 transiently
expressed in CHO cells localized to the cell membrane (Fig.
5A). Although JAM-1 is localized to the cell membrane,
intense staining is observed at the cell-cell contacts formed by
transfected cells (data not shown). In stably transfected
confluent T47D cells, JAM-1 showed a cobblestone-like
pattern of cellular localization specific to intercellular junctions
(Fig. 5B). Since JAM-1 was also found to localize to membrane
structures that resemble membrane ruffles in well-spread cells,
the localization of JAM-1 (Fig. 6A) was compared with F-actin
(Fig. 6B). JAM-1 was found to co-localize with F-actin at cell-
cell contacts and the membrane ruffles, but not at stress fibers
(Fig. 6C). Fig. 6D is another representation of co-localization
of JAM-1 with F-actin at the cell-cell junction.
Homophilic interaction of JAM-1
Because the most intense staining of JAM-1 was observed
where two adjacent cells made contact with each other, this
suggests that JAM-1 associates through homophilic
interactions. To test this idea, CHO cells that were expressing
high levels of JAM-1 were mixed with equal amounts of
untransfected cells and plated on coverglass chambers.
Untransfected cells did not show HA-tagged JAM-1
expression. In isolated cells, JAM-1 was found uniformly on
th  cell membrane. However, JAM-1 localizes only to the cell-
cell junctions formed by two transfected cells (Fig. 7A,B,
bottom), and not to the cell-cell junctions formed by a
transfected cell with an untransfected cell (Fig. 7B, top),
suggesting that JAM-1 may facilitate cell adhesion through
homophilic binding. 
Fig. 4. Regional mapping of the JAM-1 gene by FISH.
Fluorescently labeled JAM-1 cDNA was hybridized to
normal human lymphocyte chromosomes
counterstained with DAPI. Biotinylated JAM-1 cDNA
was detected with FITC-labeled avidin and anti-avidin.
Separate images of metaphases (B) or partial spreads 
(C), and of the hybridization signal on chromosome 1
(arrow) were captured and overlaid electronically using
a CCD-cooled camera with software from the IPLab
Spectrum module (Scanalytics). The arrowheads in B
indicate homologous pair of chromosome 1. The FISH
signal localized the gene to 1q21.1-21.2. A Unigene
database search revealed that the JAM-1 gene is
localized between microsatellite markers D1S2705 and
D1S2768 (A). 
Fig. 5. Surface expression of recombinant JAM-1. (A) CHO cells
were transiently transfected with an expression vector producing
HA-tagged JAM-1. 24 hours after transfection, cells were stained
with an anti-HA antibody followed by a Texas Red-conjugated
secondary. Cells were observed under confocal microscopy. JAM-1
localizes to the membrane of transfected CHO cells. (B) Stably
transfected T47D cells were allowed to grow to confluency before
fixing. JAM-1 localizes to the cell-cell junction. 
544
Adhesion of human platelets to JAM-1-
expressing CHO cells
To determine if JAM-1 facilitates platelet adhesion to
the cells that express JAM-1, CHO cells that were
mock transfected or transfected with JAM-1 were
plated to form a confluent monolayer. Freshly
isolated human platelets were allowed to bind to the
monolayer, and bound platelets were visualized by
using a fluorescently labeled cyclic RGD peptide that
specifically binds to the platelet surface integrin
αIIbβ3. Fewer than five platelets/field bound to the
mock-transfected cells (Fig. 8B), whereas ~35
platelets/field, bound to the JAM-1-transfected cells
(Fig. 8A). In three separate experiments, we found
that about sixfold more platelets bound to CHO cells
expressing JAM-1 than to non JAM-1-expressing
cells (Fig. 8C). The increased binding of platelets to
JAM-1-expressing cells was consistent with the level of JAM-
1 expression on the cell surface (data not shown). These results
indicate that JAM-1 facilitates platelet adhesion to JAM-1-
expressing cell monolayers, probably through homophilic
interactions.
DISCUSSION
Many platelet surface glycoproteins serve as antigens for
autoantibodies (Beardsley, 1990; McMillan, 2000; Wadenvik
et al., 1998). A number of monoclonal antibodies specific to
these antigens stimulate platelets, leading to granular secretion
and aggregation (Carroll et al., 1990; Jennings et al., 1985;
Perutelli and Mori, 1993; Worthington et al., 1990). We have
previously purified and characterized a novel platelet surface
glycoprotein as an antigen for the stimulatory monoclonal
antibody F11 (Naik et al., 1995). Molecular cloning of this
surface antigen revealed that it is a novel type 1 membrane
protein and a member of the Ig superfamily of cell adhesion
molecules. Deduced amino acid sequence analysis indicates
that it is ~69% identical to the recently cloned murine
junctional adhesion molecule, JAM (Martin-Padura et al.,
1998), and that it is identical to the human homolog of JAM
(Ozaki et al., 1999; Williams et al., 1999). Recently, another
group independently reported the cloning of the platelet F11
receptor, F11R, which is identical to our JAM-1 (Sobocka et
al., 2000). Sequence data of each of these proteins have been
deposited in the database as separate entries under separate
names (JAM-1, AF111713; F11R, AF207907). Very recently,
two Ig-family members named VE-JAM and JAM-2 have been
identified (Palmeri et al., 2000). Although similar in size and
in their intracellular distribution, these newly identified
members have different tissue distributions than JAM-1. VE-
JAM is not expressed on platelets and leukocytes whereas,
JAM-2 is predominantly expressed in the heart (Palmeri et al.,
2000). Interestingly, JAM-2 and VE-JAM are distinct products
of genes mapped to the same locus on chromosome 21
(21q21.2), in contrast to JAM-1, which is localized to
chromosome 1. 
It has been reported that JAM-1 has two V-type Ig domains
and hence may belong to a novel family of cell adhesion
molecules (Ozaki et al., 1999; Williams et al., 1999). However,
Sobocka et al. predicted the presence of two C2-type domains
(Sobocka et al., 2000). Our sequence analysis supports the
prediction of two C2-type domains based on the classification
of Ig-domains (Williams, 1987; Williams and Barclay, 1988).
The main structural difference between V-type and C2-type
domains is that the V-domain has an extra loop in the middle,
loop D that links E and F strands (Harpaz and Chothia, 1994;
Williams, 1987; Williams and Barclay, 1988). Consequently,
V-type and C2-type domains have different lengths between
the cysteine residues that forms the disulfide bridges. The V-
type domains usually have 65-75 amino acid residues, whereas
C2-type domains have 55-60 residues (Harpaz and Chothia,
1994). 
Amino acid sequence analysis indicates the presence of two
putative N-glycanase sites in the second Ig domain of the
extracellular domain of JAM-1. This is in contrast to the
findings of a single N-glycosylation site in previous reports
(Ozaki et al., 1999; Sobocka et al., 2000). The presence of two
glycosylation sites supports our previous finding that F11
recognizes a doublet of 35 and 32 kDa in platelet extract that
was converted into a single 29 kDa core protein upon N-
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Fig. 6. Co-localization of JAM-1 with membrane ruffles at
the cell-cell junction. CHO cells transfected with JAM-1
were stained with anti-HA antibody for JAM-1 and with
FITC-labeled phalloidin for F-actin. (A) Intense JAM-1
staining is found at the cell-cell junctions (red). 
(B) Phalloidin staining of F-actin stress fibers and
membrane ruffles (green). (C) Merged image from 
A,B. JAM-1 colocalizes with F-actin at the cell-cell
junction and membrane ruffles. However, it does not
localize to the stress fibers.(D) Another representation of
co-localization of JAM-1 and F-actin at cell-cell junctions. 
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glycanase treatment (Naik et al., 1995). Since the molecular
mass of a single N-linked sugar moiety is generally of the order
of 3-4 kDa (Scott et al., 1989), it is possible that the 35 kDa
form has two such sugar groups, and the 32 kDa form has one.
The cytoplasmic domain of JAM-1 has several putative
phosphorylation sites for PKC and other protein kinases. This
is in agreement with our previous finding that JAM-1 is
phosphorylated in vitro and in vivo by PKC (Naik et al., 1995),
which has recently been confirmed by Ozaki et al. (Ozaki et
al., 2000). Other structural features of JAM-1 include two
tyrosine residues in a context similar to the cytoplasmic
domain of PDGFR, which is capable of binding to SH2
domain-containing proteins (Jackson et al., 1997b). These two
tyrosines are also conserved in mouse JAM. Interestingly,
similar tyrosine residues are also present in the cytoplasmic
domain of PECAM-1, a member of the CAM family of
proteins that has been shown to bind to the SH2-containing
protein, SHP2P (Jackson et al., 1997b). PECAM-1 is also
expressed on platelet and endothelial cells and is involved in
platelet activation upon antibody crosslinking (Varon et al.,
1998). The cytoplasmic domain of JAM-1 has a conserved
motif (S/TXXV) that is capable of binding PDZ (PSD-95, discs
large, ZO-1) domains. In fact, JAM-1 has recently been found
to bind to two tight-junction proteins, ZO-1 and AF-6 through
their PDZ domains (Ebnet et al., 2000).
Structurally, JAM-1 resembles other cell adhesion molecules
(CAMs), which have a large extracellular domain containing
multiple Ig-like subdomains and a short cytoplasmic domain.
Several members of the Ig-superfamily have been shown to be
expressed in multiple forms, either as a result of alternate
splicing or as products of closely related genes (Baldwin et al.,
1994; Rahuel et al., 1996; Walsh and Doherty, 1997). For
example, PECAM-1 is expressed in different spliced forms
(Baldwin et al., 1994; Buck et al., 1993), whereas ICAM
family members ICAM-1, ICAM-2, and ICAM-3, are all
derived from separate genes displaying significant sequence
homology (de Fougerolles and Springer, 1992; Fawcett et al.,
1992; Vazeux et al., 1992; Wuthrich, 1992). In contrast to
murine JAM (Martin-Padura et al., 1998), multiple forms of
the human JAM-1 mRNA are expressed. The physical mapping
of JAM-1 to the long arm of chromosome 1 excludes the
possibility that JAM-1 gene products arise from homologous
genes dispersed throughout the genome. RT-PCR data suggest
that the coding region of JAM-1 does not have insertions
resulting from alternative splicing. Interestingly, the VE-JAM
message is also expressed in three forms (4.4 kb, 1.4 kb and
Fig. 7. Homophilic interaction of JAM-1 in CHO cells.
Untransfected CHO cells and CHO cells expressing HA-tagged
JAM-1 were stained with an anti-HA antibody as in Fig. 5. Two
JAM-1-expressing cells forming a contact are shown in A. 
(B) A JAM-1-expressing cell either in contact with another cell that
expresses JAM-1, or in contact with an untransfected cell. Intense
staining is observed at the place where two adjacent cells actually
make contact with each other (A). JAM-1 localizes to the cell-cell
contact formed by two cells that express JAM-1 (B, bottom) and is
not localized to the junction formed by a JAM-1-expressing cell with
an untransfected cell (B, top).
Fig. 8. Platelets adhere to CHO cells expressing JAM-1. Human platelets from PRP were allowed to adhere to JAM-1-transfected (A) and
mock-transfected (B) CHO cells, which were grown in coverglass chambers to confluency. The bound platelets were fluorescently detct d as
described in the experimental procedures. Platelets bound per field (100× oil immerson objective) were counted randomly. (C) Results of three
separate experiments presented as mean±s.e.m.
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1.2 kb), with the ~4.4 kb transcript being most abundant
(Palmeri et al., 2000). The multiple species of JAM-1 message
results from the different sizes of the 3′-UTR formed as a result
of insertion of Alu-like repetitive elements. 
Platelets have been shown to express JAM-1 constitutively
on their surface. Adhesion of platelets to a monolayer of CHO
cells expressing JAM-1 on their surface but not to the mock-
transfected cells suggests that JAM-1 may facilitate cell-cell
adhesion through homophilic interactions. Ozaki et al. have
shown that the combined treatment of endothelial cells with
proinflammatory cytokines, TNF-α and IFN-γ, causes the
disappearance of JAM-1 from the intracellular junctions and
its redistribution on the cell surface (Ozaki et al., 1999). It is
thus possible that the JAM-1 exposed on the activated
endothelial cell surface may facilitate the interaction of
circulating leukocytes and platelets with the endothelium.
However, the JAM-1-specific mAb failed to inhibit leukocyte
transmigration through a monolayer of endothelial cells (data
not shown). It is possible that our anti-JAM-1 mAb may not be
a function-blocking antibody. Antibody against murine JAM
has been reported to block leukocyte transmigration into
the CNS induced by cytokines (Del Maschio et al., 1999).
Although our results indicate that JAM-1 is capable of
homophilic interactions, its heterophilic interactions with other
cell-surface proteins not expressed in CHO cells cannot be
excluded. Several members of the CAM family are known to
interact by both homophilic and heterophilic interactions
(Muller, 1995; Wu and Lian, 1997).
Like most of the known stimulatory monoclonal antibodies,
platelet stimulation by F11 requires binding to its antigen,
JAM-1, through its Fab portion, and to the FcγRII receptor
through its Fc portion (Naik et al., 1995). This receptor
crosslinking is necessary for the full platelet activation
response. However, in the absence of Fc receptor crosslinking,
F11 is capable of potentiating the responses of suboptimal
stimuli of physiological agonists such as ADP and thrombin.
This crosstalk between different signaling pathways suggests
that the cytoplasmic tails of the respective membrane receptors
may mediate the stimulation of common intracellular
regulatory circuitry. We have previously shown that JAM-1 is
phosphorylated as a result of antibody binding (Naik et al.,
1995). It is therefore possible that JAM-1 may be involved in
transmembrane signaling. Further characterization of the
signaling pathway induced by JAM-1 is in progress. 
It has now been demonstrated that Ig-like CAMs and
selectins on endothelial cells also function as outside-in
signaling receptors (Gurubhagavatula et al., 1998; Suter et al.,
1998). The signaling events induced by these CAMs include a
rise in intracellular Ca2+, protein phosphorylation and
cytoskeletal rearrangements. It has also been shown that
platelet-endothelial cell adhesion molecule 1 (PECAM-1)
becomes phosphorylated and associates with the platelet
cytoskeleton upon platelet activation (Newman et al., 1992).
Our previous finding of JAM-1 as the co-receptor for a platelet-
activating antibody strongly suggests that JAM-1, in addition
to cell-cell adhesion, may also be involved in intracellular
signaling. Thus, it may appear that this protein has two
independent functions: one structural, which is related to the
formation of tight junctions through homophilic interactions,
and the other related to signal transduction through heterophilic
interactions. These two distinct functions may be cell specific.
Although JAM-1 may serve as an antigen on the plasma
membrane for autoantibodies during certain autoimmune
disorders, its physiological ligand on other cells is yet to be
identified. The identification of this physiological ligand will
help to define the physiological function of this molecule. 
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